Latest news from Argenta

20/05/2016

AML Riverside is set to supply the United States market

We started the year with two people, no products, infrastructure, nor quality system and so the last four months have been very busy.

Today, we are excited to share big news with you: in May the facility had a successful US Food and Drug Administration (FDA) inspection with no FDA Form 483 issued, and we are now set to manufacture solid dose and liquid products for the US Market and beyond.

Since January 4th, when we opened our Fort Dodge facility, we have hired 44 employees specialising in operations and quality. Over these past few months, the team at AML Riverside have commenced making a non-regulated product and, with great support from our New Zealand team, have been busy ensuring everything is in order to meet the requirements of the FDA. They have made sure all operational and GMP infrastructure necessary to manufacture FDA regulated products are in place.

AML Riverside can now begin manufacturing a variety of products from tablets to liquids; a range that complements and adds to the products coming out of our Auckland, New Zealand facility.

The Commercialization teams operating out of Kansas and New Zealand are supporting the transfer of several products to the AML Riverside facility, with GMP manufacturing scheduled to start in June.

Argenta is fully committed to the US market and look forward to talking with our clients about our AML Riverside facility and exploring opportunities for collaboration that provide mutual benefit.

For more information, contact enquiry@argentaglobal.com.